

CURRICULUM VITAE ABREVIADO (CVA)

Important: the Curriculum vitae cannot exceed 4 pages

Part A. PERSONAL INFORMATION

First name	Eduardo		
Family name	Weruaga Prieto		
Gender (*)	male	Birth date	06/02/1968
ID number	DNI: 10076566J		
e-mail	ewp@usal.es	URL Web	
Open Researcher and Contributor ID (ORCID) (*)	0000-0003-2887-5506		

(*) Mandatory

A.1. Current position

Position	Full Professor (Cell Biology)		
Initial date	26/07/2017		
Institution	Universidad de Salamanca (USAL)		
Department/Center	Institute for Neuroscience of Castile and Leon (INCyL)		
Country	Spain	Telephone Number:	923294500 #5324
Key words	cell therapy, neural plasticity, neurodegeneration, neuroscience, olfaction, regenerative medicine, stem cells		

A.2. Previous positions (research activity, interruptions, indicate total months)

Period	Position/Institution/Country/Interruption cause
2015	Full Professorship tenure track.
2005-2017	Associate Professor (tenure). USAL.
2003	Associate Professorship tenure track.
2002	Researcher (Spanish Foreign Office). Institute Pasteur, Paris.
2002-2004	Adjunct Professor. USAL
1998; 1999; 2001	Postdoctoral researcher (NATO Program). Ege University. Izmir, Turkey.
1997-2001	Assistant Professor. University of Salamanca, Spain
1995-1996	Research Assistant. Dpt. Cell Biology & Pathology. USAL
1993	Research stays (PhD Student). Universität Heidelberg, Germany
1992-1995	PhD student + Assistant in Human Histology. Université de Fribourg/Universität Freiburg, Switzerland.
1989-1991	Pregraduate Fellow. Ministry of Education-USAL. Dpt. Cell Biology

A.3. Education

PhD, Licensed, Graduate	University/Country	Year
Doctor in Neuroscience (Ph.D.)	Universidad de Salamanca	1999
Doctor <i>Rerum Naturalium</i> (Ph.D.)	Université de Fribourg Suisse (Switzerland)	1995
Lic. Biología (B.Sc., M.Sc.)	Universidad de Salamanca	1991

(Include all the necessary rows)

Part B. CV SUMMARY (max. 5000 characters, including spaces)

- 2 PhD theses, National tenure dissertation, National full professorship dissertation.
- **78** indexed publications **35Q1/154D1**
- Total citations (since 1992): **2.261** Total citations (since 2021): 532
- <https://produccioncientifica.usal.es/investigadores/56260/detalle>
- H index: **30** i10-index: **65** (Google Scholar)
- 9 chapters of scientific books. · 12 book chapters of teaching or informative nature.
- 4 multimedia CD-ROMs on Neurosciences and Histology.
- Research six years terms: **6**. 1992-2021 (currently within the 6th one)

Director of research work

- 10 Doctoral Theses supervised (2 currently in progress)
- 17 Master's theses (TFM) supervised / 8 Graduate's Theses / 14 Bachelor's theses (TFG).



Scientific management

- 13 research projects as Principal Investigator (36 as researcher of the team).
- Evaluator of scientific projects and contracts at ANECA, ANEP, UniBasq, Fund. Invest. y Progreso Junta Andalucía, Junta de Extremadura, Ataxia UK, Tatania dGeB, etc.
- Founding member of the Neurosciences Association of Castilla y León, 1999.
- Secretary-Treasurer of the Neurosciences Association of Castilla y León, 2006-2012.
- Member of the Board of Directors of the ROE: 2009-2018.
- Member of the Training Committee SENC.
- 234 communications to national and international congresses.

Specialized and postgraduate teaching

- Director of the master's degree in Neurosciences of the USAL (since October 2015).
- Director of 12 and lecturer of 45 specialization courses on Biosciences and Neuroscience.
- Educational innovation projects: 22, of which 7 as coordinator.
- 18 conferences on neurosciences.

Awards

- 5 research awards. Colegio de Médicos de Valladolid.
- María de Maeztu Award to the Scientific Excellence. USAL 2023.
- Gloria Vegué Award to the Educational Excellence. USAL 2025.

Scientific dissemination

- Curator of the exhibition "Neurosciences in the XXI century". Coordinator and organizer of training activities and workshops. Salamanca, 2008. Science Week 2008. General Foundation of the University of Salamanca. Sponsored by the Junta de Castilla y León, *Europa impulsada nuestro conocimiento* and European Union FEDER funds.
- Neural Landscapes. INCyL-Forum 2010. La Caixa Foundation and INCyL. Conference and round table "Addiction: Is it a disease? Salamanca, January-February 2010.
- Smell workshop. ROE and Museum of Aromas. Sta Cruz de la Salceda (BU), March 2013.
- Smell and taste workshop. Month of the brain 2013.
- Organizers: Spanish Olfactory Network and Space for Scientific Culture of the University of Salamanca. Funded by: ROE and SENC. Salamanca, May 2013.
- Workshop on smell and taste. Organized by: Instituto de Neurociencias de Castilla y León. Funded by: ROE. Salamanca, May 2013.
- Workshop on smell and taste. Organized by: Aula de Cultura Científica. General Foundation University of Salamanca. Funded by: University of Salamanca and Fundación General USAL. Salamanca, October 2014.
- Week of the brain in Salamanca: dissemination and neuroscience workshops. Institute of Neurosciences of Castilla y León. Brain Awareness Week. Salamanca, March 2015.
- City-Science Program: outreach with workshops on smell and taste. Funded by MINECO Fundación laCaixa, ROE and CSIC. Mahón, Ubrique, Plasencia, Burgo de Osma, Los Llanos de Aridane, Vilaseca, Coria, Astorga, Gáldar, Calatayud, Villena, Tudela, Cádiz, Béjar, La Orotava, Cangas del Narcea (2015-2025).
- Long-life learning for seniors. Teaching biology at "Universidad de la Experiencia", since 2008. *Universities of Castile and Leon* (Salamanca, Béjar, Ciudad Rodrigo, Benavente).

Part C. RELEVANT MERITS (sorted by typology)

C.1. Publications (max 10, see instructions)

Complete information on peer-reviewed articles can be found at the following link:

<https://pubmed.ncbi.nlm.nih.gov/?term=%28Weruaga+E%29+or+%28Weruaga-Prieto+E%29+or+%28Prieto+EW%29&sort=date>

1. HSP25 and HSP25-P-Ser15 prompt innate neuroprotection in lobe X of the cerebellum. Hernández-Pérez C, Pérez-Revueña L, Téllez de Meneses PG, Cabedo VL, Alonso JR, Díaz D*, Weruaga E*. *Int J Mol Sci* (2026) 27:1145. **Q1**
2. Model of selective neurodegeneration driven by a Ccp1 mutation leads to atypical microglia with an increased response to pathological stimuli. Pérez-Boyero D, de la Mata, A, Castillo-Sánchez J, Reverte I, Yanguas-Casás N, Ávila-Zarza C, Valero J, Alonso JR, Arévalo M-A, Ragozzino D, Weruaga E*, Díaz D*. *Brain Behav Immun* (2026) 133:106248. **D1/Q1**.



3. Specific glutamylation patterns of the cytoskeleton confer neuroresistance to Lobe X of the cerebellum in a model of childhood-onset neurodegeneration with cerebellar atrophy. Hernández-Pérez C, Calderón-García AA, Pérez-Boyero D, González-Núñez V, Weruaga E*, Díaz D*. *Int J Mol Sci* (2025) 26:10378. **Q1**
4. Intracerebellar injection of monocytic immature myeloid cells prevents the adverse effects caused by stereotactic surgery in a model of cerebellar neurodegeneration. Del Pilar C, Garrido-Matilla L, Del Pozo-Filíu L, Lebrón-Galán R, Arias RF, Clemente D, Alonso JR, Weruaga E*, Díaz D*. *J Neuroinflammation* (2024) 21:49. **D1/Q1**
5. The eNOS isoform exhibits increased expression and activation in the main olfactory bulb of nNOS knock-out mice. Pérez-Boyero D, Hernández-Pérez C, Valero J, Cabedo VL, Alonso JR, Díaz D, Weruaga E. *Front Cell Neurosci* (2023) 17:1120836. **Q1**
6. Oleoylethanolamide prevents the disease and death of Purkinje cells and ameliorates the behavioral defects in a mouse model of cerebellar neurodegeneration. Pérez-Martín E, Muñoz-Castañeda R, Moutin M-J, Ávila-Zarza CA, Muñoz-Castañeda JM, del Pilar C, Alonso JR, Andrieux A, Díaz D, Weruaga E. *Neurotherapeutics* (2021) 18:1748–67. **D1/Q1**
7. Transplantation with Lewis bone marrow induces the reinstatement of cocaine-seeking behavior in male F344 resistant rats. Assis MA, Díaz D, Ferrado R, Ávila-Zarza CA, Weruaga E, Ambrosio E. *Brain Behav Immun* (2021) 93:23-34. **D1/Q1**
8. Cytoskeleton stability is essential for the integrity of the cerebellum and its motor- and affective-related behaviors. Muñoz-Castañeda R, Díaz D, Peris L, Andrieux A, Bosc C, Muñoz JM, Janke C, Alonso JR, Moutin MJ, Weruaga E. *Sci Rep* (2018) 8:3072. **D1/Q1**
9. Differential glial activation during the degeneration of Purkinje cells and mitral cells in PCD mutant mice. Baltanás FC, Berciano MT, Valero J, Gómez C, Díaz D, Alonso JR, Lafarga M, Weruaga E. *Glia* (2013), 61:254-72. **D1/Q1**
10. Bone marrow cell transplantation restores olfaction in the degenerated olfactory bulb. Díaz D, Lepousez G, Gheusi G, Alonso JR, Lledo P-M, Weruaga E. *J Neurosci* (2012), 32:9053-8. **D1/Q1**

C.2. Congress, indicating the modality of their participation (invited conference, oral presentation, poster)

- Member of the organizing committee of two Neuroscience congresses.
- President of the organizing committee of a Neurosciences congress.
- Secretary-Treasurer of the Neurosciences Association of Castilla y León, 2006-2012.
- Member of the Spanish Olfactory Network (ROE) since its foundation, 2004.
- Member of the Board of Directors of the ROE: 2009-2018.
- 212 communications to national and international congresses.

C.3. Research projects, indicating your personal contribution. In the case of young researchers, indicate lines of research for which they have been responsible.

1. **Terapia celular en un modelo de ataxia cerebelosa: selección y mejora del linaje celular con mayor potencial neuroprotector.** Junta de Castilla y León-FEDER. Cons. Educación. SA129P20. Pls: Eduardo Weruaga & David Díaz. 2024-28. 172 k€
2. **Neural protection in bone marrow cell therapy: systemic or neural origin?** MICINN. PID2022-140456NB-I00. PIPs: Eduardo Weruaga & David Díaz López. 2023-27. 115 k€.
3. **Cooperação e transferência tecnológica para o desenvolvimento de uma nova plataforma de medicina de precisão para a Esclerose Lateral Amiotrófica.** 0145_CROSS_3DTOOL_4ALS_3_P (id:891). EP - Interreg VI A España – Portugal (POCTEP) 2021-2027. PI at USAL: J. Valero. 2024-26. 758 k€.
4. **Red Olfativa Española.** Ministerio de Ciencia e Innovación; Red de Investigación, RED2022-134081-T. IP: Laura López-Mascaraque CSIC. 2023-2025. 20 k€.
5. **Protección neuronal multifactorial: sinergia entre moléculas con actividad neuroquímica y células progenitoras modificadas genéticamente.** Ministerio de Economía y Competitividad. Programa estatal de investigación, desarrollo e innovación orientada a los Retos de la Sociedad. PID2019-106943RB-I00. IP: E. Weruaga. 2020-2023. 90 k€



6. **Terapia celular en un modelo de ataxia cerebelosa: selección y mejora del linaje celular con mayor potencial neuroprotector.** Junta de Castilla y León (FEDER). Consejería de Educación (SA129P20). IP: E. Weruaga. 2021-2023. 172 k€.
7. **Alteraciones olfativas como biomarcador temprano de contagio y evolución de CoVidD19.** Programa de apoyo a proyectos de investigación cofinanciados por FEDER Instituto Carlos III-Junta de Castilla y León. IP: JR. Alonso. 2021-2023. 172 k€.
8. **Red Olfativa Española.** Ministerio de Ciencia e Innovación; Acciones de dinamización "Redes de Investigación" RED2022-134081-T. IP: Laura López-Mascaraque CSIC. 2019-2022. 17 k€.
9. **Terapia celular y terapia farmacológica combinadas: potenciación recíproca de enfoques complementarios frente a patologías neurodegenerativas selectivas.** Ministerio de Economía y Competitividad. Programa estatal de investigación, desarrollo e innovación orientada a los Retos de la Sociedad. SAF2016-79668-R. IP: E. Weruaga. 2017-2019.
10. **Terapia Celular frente a Neurodegeneración Selectiva: Potenciación de células madre de la Médula Ósea por selección clonal, modificación genética y Farmacoterapia Complementaria.** Junta de Castilla y León (FEDER). Consejería de Educación. SA030P17. IP: E. Weruaga. 2017-2019.
11. **Terapia celular con médula ósea en neurodegeneración selectiva: empleo de la microglía derivada como vector de agentes neuroprotectores.** Programa estatal de investigación, desarrollo e innovación orientada a los retos de la sociedad (SAF2013-41175-R; Plan estatal de investigación científica y técnica y de innovación 2013-2016. Ministerio de Economía y Competitividad. IP: E. Weruaga. 2014-2016.
12. **El sistema olfativo como modelo de daño y reparación neuronal: estudio de anosmias inducidas y genéticas, y aplicación de terapia celular.** Consejería de Educación. Junta de Castilla y León (SA178U13). IP: E. Weruaga. 2013-2015.
13. **Plasticidad del sistema nervioso central adulto ante neurodegeneración selectiva. Aporte de nuevos elementos endógenos y exógenos.** Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (BFU2010-18284), subprograma BFI. Ministerio de Ciencia y Tecnología. IP: E. Weruaga. 2011-2013.

C.4. Contracts, technological or transfer merits, include patents and other industrial or intellectual property activities (contracts, licenses, agreements, etc.) in which you have collaborated. Indicate: a) the order of signature of authors; b) reference; c) title; d) priority countries; e) date; f) Entity and companies that exploit the patent or similar information, if any

- **Patent.** Method for the identification of pre-neurodegenerative neuronal dysfunction signs. P200602225. Inventors: Alonso JR, Berciano MT, Gómez C, Lafarga M, Valero J, Weruaga E. 16-02-2010. Spain.
- **Contract.** *Proyecto modelo de intervención integral en niños/as con trastornos del espectro autista: Fortalecimiento de las capacidades de los agentes e instituciones implicadas en el Departamento de Chuquisaca (Bolivia).* Artículo 83, USAL. PIs: Ricardo Canal Bedia/JR Alonso Peña. 2011-2013
- **Patent.** Biomarker for central nervous system T-cell-derived primary lymphoma, uses and methods. P202031080. Álvarez AM, Alonso JR, Díaz D, Weruaga E, Wolf A, Valerio J, Michelle J. 28-10-2020. Spain.
- **Patent.** Biomarker for central nervous system primary lymphoma, uses and methods. P202031229. Álvarez AM, Alonso JR, Díaz D, Weruaga E, Michelle J, Valerio J. 10-12-2020. Spain.
- **PROTOTRANSFER award** of market-oriented prototypes. EU. March 2018.

Salamanca, 10th May 2026